Halozyme Therapeutics, Inc. (HALO) Financial Statements

Executive TeamFinancials
SegmentsShareholders

Halozyme Therapeutics financial statements at a glance

Halozyme Therapeutics reported revenue of $1.40 billion for fiscal year 2025 (ended December 31, 2025), up 37.6% from fiscal year 2024. Net income was $316.89 million, a net margin of 22.7%, and diluted earnings per share were $2.56.

At the end of fiscal year 2025 it had total assets of $2.53 billion, total liabilities of $2.48 billion and shareholders' equity of $48.81 million, with cash and short-term investments of $142.82 million and total debt of $2.14 billion.

Its operations brought in $651.56 million of cash; capital spending was $294.74 million, leaving free cash flow of $356.82 million.

The tables below show the income statement, balance sheet and cash flow statement; the key figures of the last 5 fiscal years are at the bottom of the page.

Figures from company filings, in USD; latest fiscal year ended December 31, 2025.

HALO logo

Halozyme Therapeutics, Inc.

HALOUnited States
Healthcare
USD (Local)

Income Statement

Annual • USD

Total Revenue
1.40B
Prev Year: 1.02B
YoY: +37.6%
Operating Revenue
1.40B
Prev Year: 1.02B
YoY: +37.6%
Total Unusual Items Excluding Goodwill
-317.59M
Prev Year: 23.75M
YoY: -1437.1%
Total Expenses
594.02M
Prev Year: 463.85M
YoY: +28.1%
Total Operating Income as Reported
469.01M
Prev Year: 551.48M
YoY: -15.0%
Diluted NI Available to Com Stockholders
316.89M
Prev Year: 444.09M
YoY: -28.6%
Special Income Charges
-339.06M
Other Special Charges
5.48M
Impairment of Capital Assets
48.70M
Restructuring and Mergers Acquisition
284.89M
Gain on Sale of Securities
21.47M
Prev Year: 23.75M
YoY: -9.6%
Cost of Revenue
228.77M
Prev Year: 159.42M
YoY: +43.5%
Operating Expense
365.24M
Prev Year: 304.43M
YoY: +20.0%
Gross Profit
-
Prev Year: 855.91M
Selling General and Administrative
207.09M
Prev Year: 154.34M
YoY: +34.2%
Research and Development
81.49M
Prev Year: 79.05M
YoY: +3.1%
Depreciation Amortization Depletion
76.66M
Prev Year: 71.05M
YoY: +7.9%
Depreciation and amortization
76.66M
Prev Year: 71.05M
YoY: +7.9%
Amortization
76.66M
Prev Year: 71.05M
YoY: +7.9%
Amortization of Intangibles
76.66M
Prev Year: 71.05M
YoY: +7.9%
Operating Income
802.59M
Prev Year: 551.48M
YoY: +45.5%
Net Non Operating Interest Income Expense
-18.13M
Prev Year: -18.09M
YoY: -0.2%
Non-operating Interest Expense
18.13M
Prev Year: 18.09M
YoY: +0.2%
Other Income Expense
-317.59M
Prev Year: 23.75M
YoY: -1437.1%
Pre-tax Income
466.88M
Prev Year: 557.13M
YoY: -16.2%
Provision for Income Taxes
149.99M
Prev Year: 113.04M
YoY: +32.7%
Net Income Common Stockholders
316.89M
Prev Year: 444.09M
YoY: -28.6%
Net Income
316.89M
Prev Year: 444.09M
YoY: -28.6%
Net Income Including Non-Controlling Interests
316.89M
Prev Year: 444.09M
YoY: -28.6%
Net Income from Continuing Operations
316.89M
Prev Year: 444.09M
YoY: -28.6%
Basic EPS
2.64
Prev Year: 3.5
YoY: -24.6%
Diluted EPS
2.56
Prev Year: 3.43
YoY: -25.4%
Weighted Average Shares (basic)
119.84M
Prev Year: 126.83M
YoY: -5.5%
Weighted Average Shares (diluted)
123.90M
Prev Year: 129.42M
YoY: -4.3%
Net Income from Continuing and Discontinued Operation
316.89M
Prev Year: 444.09M
YoY: -28.6%
Normalized Income
532.44M
Prev Year: 425.16M
YoY: +25.2%
Interest Expense
18.13M
Prev Year: 18.09M
YoY: +0.2%
Net Interest Income
-18.13M
Prev Year: -18.09M
YoY: -0.2%
EBIT
485.00M
Prev Year: 575.23M
YoY: -15.7%
EBITDA
573.05M
Prev Year: 656.54M
YoY: -12.7%
Reconciled Cost of Revenue
217.38M
Prev Year: 149.15M
YoY: +45.7%
Reconciled Depreciation
88.05M
Prev Year: 81.31M
YoY: +8.3%
Net Income from Continuing Operation Net Minority Interest
316.89M
Prev Year: 444.09M
YoY: -28.6%
Normalized EBITDA
890.64M
Prev Year: 632.79M
YoY: +40.7%
Tax Rate for Calcs
0.321
Prev Year: 0
Tax Effect of Unusual Items
-102.04M
Prev Year: 4.82M
YoY: -2217.4%
Total Unusual Items
-317.59M
Prev Year: 23.75M
YoY: -1437.1%
Values in USD

Halozyme Therapeutics key figures by fiscal year

FY2025FY2024FY2023FY2022FY2021
Revenue$1.4B$1.0B$829.3M$660.1M$443.3M
Gross profit–$855.9M$636.9M$520.8M$361.9M
Operating income$802.6M$551.5M$337.6M$267.5M$275.9M
Net income$316.9M$444.1M$281.6M$202.1M$402.7M
Diluted EPS$2.56$3.43$2.10$1.44$2.74
Total assets$2.5B$2.1B$1.7B$1.8B$1.1B
Total liabilities$2.5B$1.7B$1.6B$1.7B$907.5M
Shareholders' equity$48.8M$363.8M$83.8M$169.8M$197.0M
Cash and short-term investments$142.8M$596.1M$336.0M$362.8M$740.9M
Total debt$2.1B$1.5B$1.5B$1.5B$876.7M
Operating cash flow$651.6M$479.1M$388.6M$240.1M$299.4M
Capital spending$294.7M$10.7M$15.3M$4.8M$1.5M
Free cash flow$356.8M$468.4M$373.3M$235.3M$298.0M

In USD. Fiscal years as reported by the company; statements on this page go back to fiscal year 2014.

Questions and answers

What was Halozyme Therapeutics's revenue in fiscal year 2025?

$1.40 billion, up 37.6% from $1.02 billion in fiscal year 2024.

How much profit does Halozyme Therapeutics make?

Halozyme Therapeutics reported net income of $316.89 million for fiscal year 2025 (22.7% of revenue); operating income was $802.59 million.

How much cash and debt does Halozyme Therapeutics have?

At the end of fiscal year 2025: cash and short-term investments of $142.82 million and total debt of $2.14 billion.

What is Halozyme Therapeutics's free cash flow?

$356.82 million in fiscal year 2025 (operating cash flow of $651.56 million minus capital spending of $294.74 million).

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.
LinkedInLinkedInXXYouTubeYouTube